Juvenile recurrent respiratory papillomatosis treated with combined erlotinib and celecoxib: Initial report

Int J Pediatr Otorhinolaryngol. 2020 Oct:137:110194. doi: 10.1016/j.ijporl.2020.110194. Epub 2020 Jul 10.

Abstract

Recurrent respiratory papillomatosis (RRP) is a chronic disease caused by human papillomavirus (HPV). RRP is a clinical challenge because of the high recurrence rate, poor surgery response, extension to tracheobronchial tree and because of the risk of malignancy in some cases. There is no consensus on which adjuvant therapy is better for those patients with highly recurrent course. Because papilloma cells overexpress the epidermal growth factor receptor (EGFR), together with an increased expression of COX-2 and prostaglandin E2, the combination of erlotinib and celecoxib seems plausible, and could be proposed for patients with poor response to previous lines of treatment.

Keywords: Celecoxib; Erlotinib; Juvenile-onset recurrent respiratory papillomatosis; Larynx; Papillomatosis.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Antineoplastic Agents / therapeutic use*
  • Celecoxib / therapeutic use*
  • Child
  • Child, Preschool
  • Combined Modality Therapy
  • Cyclooxygenase 2 Inhibitors / therapeutic use*
  • Erlotinib Hydrochloride / therapeutic use*
  • Female
  • Humans
  • Papillomavirus Infections / drug therapy*
  • Papillomavirus Infections / surgery
  • Respiratory Tract Infections / drug therapy*
  • Respiratory Tract Infections / surgery
  • Retreatment
  • Young Adult

Substances

  • Antineoplastic Agents
  • Cyclooxygenase 2 Inhibitors
  • Erlotinib Hydrochloride
  • Celecoxib

Supplementary concepts

  • Recurrent respiratory papillomatosis